g., all cancers have proliferation advantage compared to non-cancerous cells) coupled with the observation that this complex is associated with several different cancer types (presence of TIM mutation in breast cancer; induction of doxorubicin-mediated cytotoxicity in colon cancer cells upon TIM knockdown; activation of Myc by TIM) prompted us to speculate that TIM/TIPIN could be associated with and confer some growth advantage to melanoma cells. Here, MYC is linked to breast carcinoma.